Cellectis S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLLS research report →
Range $1.3 – $3
Price Chart
About the company
Cellectis S. A. , a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology.
- CEO
- Andre Choulika
- IPO
- 2015
- Employees
- 229
- HQ
- Paris, IF, FR
Get TickerSpark's AI analysis on CLLS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $92.76M
- P/E
- -0.79
- PEG
- 0.01
- P/S
- 2.87
- P/B
- -5.70
- EV/EBITDA
- -1.68
- Div Yield
- 0.00%
- Gross Margin
- 42.55%
- Op Margin
- -540.42%
- Net Margin
- -505.90%
- ROE
- -319.92%
- ROIC
- -167.58%
Latest fiscal year · YoY change
- Revenue
- $72.95M+75.8%
- Gross Profit
- $63.15M+95.4%
- Op Income
- $-33,076,000
- Net Income
- $-67,593,000-83.9%
- EPS
- $-0.68-65.9%
- OCF Growth
- -281.6%
- FCF Growth
- -317.7%
- 52W High
- $5.45
- 52W Low
- $0.88
- 50D MA
- $1.23
- 200D MA
- $2.85
- Beta
- 3.20
- RSI (14)
- 38
- Avg Volume
- 115.00K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cellectis is pivoting away from legacy cell therapy and advancing two in vivo gene-editing programs, with cash runway now guided into the second half of 2028.· November 13, 2026
- The company is repositioning around .HEAL-101 and .HEAL-201 after stopping lasme-cel and eti-cel development.
- Preclinical .HEAL-101 data showed up to 70% APOC3 editing and a 76% triglyceride reduction in a diseased mouse model.
- .HEAL-201 showed more than 90% PCSK9 suppression in preclinical testing; LDL-C data were not disclosed yet.
- Cash and cash equivalents, restricted cash, and fixed-term deposits were $149 million at September 30, 2026, down from $211 million at year-end 2025.
- Management says the post-realignment cash runway should last into the second half of 2028, beyond expected first clinical data for both lead programs.
For the nine months ended September 30, 2026, consolidated revenues and other income were $19.9 million versus $67.4 million a year earlier, a decline of $47.5 million, mainly due to lower activity under the AstraZeneca collaboration. Consolidated R&D expenses were $108.8 million versus $69.1 million, up $39.7 million, driven largely by a $34.9 million strategic transformation impact including a $26.6 million impairment loss, $6.2 million of termination benefits, and $2.1 million of closeout costs. SG&A was $17.5 million versus $15.0 million, up $2.5 million. The company reported a consolidated net gain of $5.2 million for the nine-month period versus a net financial loss of $25.6 million last year, helped by changes in fair value measurements and lower FX losses. Cash equivalents, restricted cash, and fixed-term deposits totaled $149 million as of September 30, 2026, versus $211 million at December 31, 2025. Management did not give quarterly revenue or EPS guidance; instead, it said the current focus is executing the transformation, advancing HEAL-101 and HEAL-201, and funding restructuring costs, with cash runway into the second half of 2028 once the realignment is complete.
André Choulika framed the quarter as a strategic reset, saying Cellectis has transformed into an in vivo gene-editing company focused first on severe dyslipidemias. He emphasized that the company is prioritizing a single-injection approach with long-lasting potential and that the legacy cell therapy programs were stopped despite the difficulty of that decision. His tone was confident and forward-looking, repeatedly pointing to 2027 as the next major inflection point for the pipeline.
Arthur Stril highlighted that this is a transition quarter and detailed the cost impact of the strategic shift. He said global headcount is expected to be reduced by up to 70% from the pre-transition level over 2026 and 2027, subject to consultation and labor-law requirements. He also cited cash of $149 million at September 30, 2026, down from $211 million at year-end, and said the company expects runway into the second half of 2028 after the realignment is fully implemented. He pointed to one-off transformation costs, including the $26.6 million impairment loss, termination benefits, and program closeout expenses, while stressing cash will now be focused on HEAL-101, HEAL-201, and new candidates.
Analysts pressed on whether .HEAL-101 needs triglyceride lowering closer to 80% or whether 50%-60% would be enough, and management said they expect efficacy at least as good as current treatments and care deeply about getting patients below 500 triglycerides. On .HEAL-201, management said LDL-C reduction data were not yet public and would come later. Other questions focused on why Cellectis chose APOC3 over ANGPTL3, with management saying APOC3 is the better target for severe hypertriglyceridemia, and on whether the China IIT sites and dose escalation plan are set, with management saying sites are chosen, the principal investigator is highly experienced, and the trial should start at an effective dose with escalation still expected.
Management believes the preclinical package is strong enough to support clinical progress, with .HEAL-101 showing liver-restricted editing and a 76% triglyceride reduction in a disease model. The company also said the China investigator-initiated trial remains on track, preliminary .HEAL-101 data are expected in the second half of 2027, and .HEAL-201 preliminary data are expected in the first half of 2028. Management sounded optimistic that the new focus could create value while preserving a runway into the second half of 2028.
The quarter reflects a sharp strategic retreat from legacy programs, including stopping lasme-cel and eti-cel, which required restructuring charges and a planned up to 70% headcount reduction. Revenue fell year over year, and R&D costs rose materially because of the transformation-related impairment and closeout expenses. Key clinical risks remain: .HEAL-201 LDL-C data are not yet disclosed, .HEAL-101 is still preclinical, and the China program depends on regulatory and execution progress before meaningful human data arrive in 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.3%
- Shares Outstanding
- 100.73M
- Float Shares
- 85.92M
of shares held by institutions
27 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| B Group, Inc. | 3.28M | 0 |
| Long Focus Capital Management, LLC | 2.74M | ▼ 2.25K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 2.64M | ▼ 533.74K |
| Blackrock, Inc. | 246.41K | ▲ 20.97K |
| Nomura Asset Management International Inc. | 226.88K | 0 |
| Morgan Stanley | 86.37K | ▲ 911 |
| Lpl Financial LLC | 85.59K | ▲ 1.18K |
| Susquehanna International Group, Llp | 50.45K | ▼ 15.49K |
| Ubs Group AG | 47.83K | ▲ 13.91K |
| Bnp Paribas Financial Markets | 37.50K | ▼ 2.60K |
| Delaney Dennis R | 24.00K | 0 |
| Hrt Financial LP | 23.68K | ▲ 23.68K |
Held by 5 ETFs
Biggest fund positions in CLLS by dollar value.
Our CLLS coverage
Recent articles, reports, and earnings notes.
No research on CLLS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLLS report →Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
What Cellectis (CLLS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 13
Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activités
globenewswire.com · Nov 12
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com · Nov 12
Cellectis to Report Third Quarter Financial Results on November 12, 2026
globenewswire.com · Nov 9
Cellectis présente de nouvelles données précliniques démontrant une édition efficace du gène APOC3 et une réduction marquée des triglycérides avec .HEAL-101 à l’ESGCT 2026
globenewswire.com · Oct 27
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
globenewswire.com · Oct 27
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
prnewswire.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.